Home
Conditions
Refractory Follicular Lymphoma

Clinical trial condition

Refractory Follicular Lymphoma

Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

35 public trials 6 recruiting studies

Refine in advanced search Browse all conditions

Refractory Follicular Lymphoma trial results

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

NCT06948786

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +59 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

NCT05848765

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: NHS Grampian Aberdeen, United Kingdom

Belfast Health & Social Care Trust Belfast, United Kingdom

University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom

Blackpool Teaching Hospitals NHS Foundation Trust Blackpool, United Kingdom

View all 25 locations

View Trial Details

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887

Conditions: B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
Locations: Mayo Clinic in Florida Jacksonville, Florida, United States

View Trial Details

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT02992522

Conditions: B-Cell, B-Cell Lymphoma, Unspecified, Burkitt Lymphoma, +30 more
Locations: Emory University Atlanta, Georgia, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, not recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

Yale University New Haven, Connecticut, United States

University of Kansas Clinical Research Center Fairway, Kansas, United States

University of Kansas Cancer Center Kansas City, Kansas, United States

View Trial Details

Active, not recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800

Conditions: Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

NCT01849263

Conditions: Grade 3a Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Florida Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States

View all 13 locations

View Trial Details

Refractory Follicular Lymphoma

Refractory Follicular Lymphoma trial results

Related conditions